Transcriptomic Profiling and Drug Repurposing Identify Fostamatinib as a Candidate Therapeutic Agent for IgG4-Related Sialadenitis

Clicks: 42
ID: 320862
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #14 of 51 articles by views in modern rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To identify therapeutic candidates for IgG4-related sialadenitis, a manifestation of IgG4-related disease characterized by IgG4-positive plasma cell infiltration and limited treatment options beyond glucocorticoids, using transcriptomic profiling and in silico drug repurposing. METHODS: Submandibular gland tissues from 49 patients with IgG4-related sialadenitis and 3 controls were analyzed by RNA sequencing. Differentially expressed genes were screened against DrugBank to identify druggable targets. Candidate drugs were prioritized based on their ability to modulate disease-associated gene signatures. Molecular docking was performed to evaluate binding affinities to key targets. RESULTS: Transcriptomic analysis revealed upregulation of immune-related pathways. DrugBank integration identified fostamatinib as a top candidate targeting multiple kinases, including SYK, BTK, and JAK3. Docking analysis demonstrated favorable binding affinity, particularly to BTK. CONCLUSION: This integrative approach highlights fostamatinib as a promising therapeutic candidate and supports a role for the SYK-BTK axis in IgG4-RD pathogenesis, suggesting a potential alternative to glucocorticoids.
Reference Key
openalex_W7168146980 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Motohisa Yamamoto, Ryuta Kamekura, Masaaki Uehara, Yuta Ichii, Kenichi Takano
Are you one of these authors? Claim your profile
Journal modern rheumatology
Year 2026
DOI
10.1093/mr/roag059
URL
https://doi.org/10.1093/mr/roag059
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.